129 related articles for article (PubMed ID: 9367714)
1. Cisplatin, epirubicin, and ifosfamide versus cisplatin, epirubicin, and cyclophosphamide in clear cell carcinoma of the ovary.
Nishida T; Sugiyama T; Yakushiji M
Gynecol Oncol; 1997 Nov; 67(2):230. PubMed ID: 9367714
[No Abstract] [Full Text] [Related]
2. [A case of neo-JP therapy in the treatment of ovarian carcinoma].
Matsunami K; Takagi H; Hasegawa Y
Gan To Kagaku Ryoho; 1995 Jan; 22(1):153-5. PubMed ID: 7826073
[No Abstract] [Full Text] [Related]
3. [A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].
Iwasaki K; Komuro Y; Masumoto N; Asaoka K; Ishitani K
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1483-6. PubMed ID: 10500539
[TBL] [Abstract][Full Text] [Related]
4. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
5. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
6. Sequential high dose-density chemotherapy in advanced ovarian cancer.
Tognoni A; Pronzato P; Cadenotti L; Ghio E; Manna N; Pensa F; Marino L
Anticancer Res; 2000; 20(5C):3957-61. PubMed ID: 11268483
[TBL] [Abstract][Full Text] [Related]
7. [Carboplatin/epirubicin/prednimustine (Sterecyt) as an adjuvant chemotherapy combination in ovarian cancer treated by radical surgery].
Pickel H
Gynakol Rundsch; 1989; 29 Suppl 2():357-8. PubMed ID: 2693256
[No Abstract] [Full Text] [Related]
8. Advanced malignant rhabdoid tumor of the ovary effectively responding to chemotherapy: a case report and review of the literature.
Banzai C; Yahata T; Sasahara J; Kashima K; Fujita K; Nishikura K; Ajioka Y; Motoyama T; Tanaka K
Gynecol Oncol; 2007 Apr; 105(1):261-5. PubMed ID: 17292455
[TBL] [Abstract][Full Text] [Related]
9. A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Fruscio R; Colombo N; Lissoni AA; Garbi A; Fossati R; Ieda' N; Torri V; Mangioni C
Br J Cancer; 2008 Feb; 98(4):720-7. PubMed ID: 18253120
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy with cisplatin and cyclophosphamide in FIGO I-II epithelial carcinoma of the ovary: preliminary results].
Chiara S; Conte PF; Bruzzone M; Falcone A; Rosso R; Ragni N; Bentivoglio G; Foglia G; Pescetto G
G Ital Chemioter; 1985; 32(1):67-9. PubMed ID: 3830795
[No Abstract] [Full Text] [Related]
11. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
13. High-dose intensity regimens with epirubicin in ovarian cancer.
Vermorken JB
Pathol Biol (Paris); 1992 Nov; 39(9):833. PubMed ID: 1538894
[No Abstract] [Full Text] [Related]
14. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy in advanced forms of carcinoma of the ovary].
Calciati A; Clerico M; Donadio M; Giaccone G
Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
[No Abstract] [Full Text] [Related]
17. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
18. Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeks.
Obermair A; Vavra N; Kurz C; Helmer H; Sevelda P; Pehamberger K
Gynecol Oncol; 1995 Jun; 57(3):436. PubMed ID: 7774853
[No Abstract] [Full Text] [Related]
19. Cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary.
Wheelock J; Hancock K; Smith K
Cancer Treat Rep; 1987 Dec; 71(12):1275-6. PubMed ID: 3690537
[No Abstract] [Full Text] [Related]
20. [Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)].
Sakaihara M; Sakai K; Hara Y; Kataoka S; Tabata M; Hanatani K; Hareyama H
Gan To Kagaku Ryoho; 2000 Jan; 27(1):127-30. PubMed ID: 10660745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
